Spark Therapeutics Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 16 of 18 Posts
1 2
Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition
Article By: Benzinga Tuesday, December 17, 2019 10:00 AM EST
Roche Holding has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc. the companies announced Tuesday.
In this article: RHHBY, ONCE
Read
Small Cap Biotechs Lead The Market In 2019 Up 20% YTD
Article By: Rod Raynovich Thursday, February 28, 2019 12:20 PM EST
Gene Therapy stocks soar on Spark (ONCE) Deal: BLUE, CRSP, RARE; and XBI up 4.2%.
In this article: ONCE, RARE, DHR, GE, XBI, BLUE, CRSP, IWM, XLV, MRK, RHHBY, BMY, CELG, LOXO, LLY, GNMK, AMRN, TDOC
Read
Roche Acquires Spark Therapeutics For $114.50 Per Share, A 122% Premium
Article By: The Fly Monday, February 25, 2019 7:23 AM EST
Spark Therapeutics announced that it has entered into a definitive merger agreement for Roche to fully acquire Spark Therapeutics at a price of $114.50 per share in an all-cash transaction.
In this article: RHHBY, ONCE
Read
Citi Upgrades Spark Therapeutics To Buy With Shares Down Nearly 30%
Article By: The Fly Tuesday, August 7, 2018 3:03 PM EST
The analyst also views the company as a potential takeover candidate.
In this article: ONCE
Read
5 Best-Rated Stocks Trending Into 2018
Article By: TipRanks Sunday, December 24, 2017 1:34 PM EST
Which 5 stocks have all the top analysts buzzing right now? We crunched the data and pinpointed five very compelling ‘strong buy’ stocks that are trending into 2018.
In this article: AMZN, MU, ONCE, AERI, SGH
Read
4 Momentum Stocks To Add To Your Portfolio Now
Article By: Modest Money Thursday, September 14, 2017 10:51 AM EST
Momentum stocks are hot stocks that are trending higher and have the consensus opinion and business model behind them to continue going higher.
In this article: WTW, STMP, TAL, ONCE
Read
HH Biotech Bonanza: The Next Leg Up For Biotech Stocks
Article By: Tarun Chandra, CFA Friday, September 1, 2017 8:05 PM EST
The Biotechnology sector remains one of the top performing sectors this year with the benchmark Nasdaq Biotechnology Index of biotech stocks, as represented by the biotech ETF (IBB​), gaining 17% in the first half.
In this article: NVS, PFE, IBB, GILD, VRTX, XBI, XLV, ONCE, LABU
Read
Income Trade Opportunity For 12% In 28 Days
Article By: Greg Group Saturday, August 19, 2017 7:47 PM EST
Option selling offers another method to diversify investing strategies beyond traditional dividend investing. We have combined technical stock events with our strategy to identify high returns option selling opportunities.
In this article: ONCE
Read
5 Stocks With Rising Analyst Coverage
Article By: Zacks Investment Research Friday, April 22, 2016 7:31 AM EST
Interestingly, stocks typically see an incremental upward price movement with new analyst coverage compared to what they witness with continuation of existing analyst coverage.
In this article: IBKR, AXDX, ONCE, YRD, VSAR
Read
2015 In Review: IPO Winners And Losers
Article By: ValueWalk Wednesday, December 30, 2015 10:14 AM EST
This year didn’t provide the most enticing environment for an IPO. A total of 72 VC-backed U.S. companies have gone public in 2015 so far, raising $8 billion in their combined offerings—both totals down from last year,
In this article: BOX, ONCE, APIC, FIT, SQ, TEAM, FLKS
Read
Early Stage Status For Dimension Therapeutics Keeps Us Cautious On This IPO
Article By: Don Dion Friday, October 23, 2015 11:59 AM EST
Dimension Therapeutics expects to raise $82.5 million in its upcoming IPO. Based in Cambridge, Massachusetts, it is a biotechnology company with a gene therapy platform for developing treatments for rare diseases associated with the liver.
In this article: NVO, PFE, QURE, ONCE, BXLT, DMTX
Read
Insider Weekends – October 17, 2015
Article By: Asif Suria Saturday, October 17, 2015 5:24 PM EST
Insider buying and selling declined last week compared to the week prior. Insider transactions are likely to stay muted over the next week or two as we get into the thick of earnings season.
In this article: APO, CRM, OPK, ADGE, CPLA, COST, ROVI, ONCE, RHP
Read
E Spark Therapeutics Reports Positive Phase 3 Results In Patients With Rare Blindness
Article By: Terry Chrisomalis Monday, October 5, 2015 6:54 PM EST
Shares of Spark Therapeutics ended the day up 25% after reporting positive phase 3 results for its SPK-RPE65 gene therapy.
In this article: ONCE Also: CLDN, AAVL
Read
Uncertainty Weighs Down On The Market - Markets This Morning
Article By: Amigobulls Wednesday, September 30, 2015 2:52 PM EST
The factors that set this bear market in motion – cuts in margin debt, low commodity prices, Chinese uncertainty – remain in place.
In this article: PBR, STO, VRX, XOM, LNG, GLNCY, VLKAY, IBB, AAPL, AMZN, COMP, FB, SPX, DJI, QURE, AAVL, ONCE
Read
E Celladon's Advanced Heart Failure Treatment Fails In Mid-Stage Study
Article By: Terry Chrisomalis Monday, April 27, 2015 10:53 AM EST
Shares of Celladon are down 70% after announcing that Mydicar failed to produce significant results in advanced heart-failure patients.
In this article: CLDN, BLUE, ONCE, QURE
Read
The End Of Google Is Here, Part II
Article By: InvestorsAlley Friday, March 20, 2015 5:14 PM EST
There’s no denying Google’s dominance since its 2004 IPO, but the end of this juggernaut’s growth story is here. Investors looking for life-changing returns must look elsewhere, and the best place for growth is in biotech.
In this article: GOOGL, ONCE, JUNO, IBB, XLK, QCOM, ORCL, MSFT, INTC, GILD, AMGN, CELG
Read
1 to 16 of 18 Posts
1 2